Join the AgeneBio team at these upcoming industry events.

March 1, 2018

2018 NIH Alzheimer’s Research Summit

Michela Gallagher will participate in a session on “Emerging Therapeutics” to discuss AgeneBio’s Programs targeting hippocampal hyperactivity in the Mild Cognitive Impairment phase of prodromal Alzheimer’s disease.

July 16, 2017

Alzheimer’s Association International Conference (AAIC)

Founder and CSO Michela Gallagher, PhD co-chaired a featured symposium, “The Two-Way Street Linking B-Amyloid, Tau and Neural Activity” and presented “Age-Related Network Dysfunction: Contributions of Neural Activity to Risk for Late Onset Alzheimer’s Disease.” Click title link for details.

September 13, 2016

17th International Conference on Alzheimer’s Drug Discovery

Vice President of Research and Development Sharon Rosenzweig-Lipson, PhD, presented at this international conference on Alzheimer’s drug discovery sponsored by the Alzheimer’s Drug Discovery Foundation. During the conference, Dr. Rosenzweig-Lipson was interviewed by NJTV News.

February 23, 2016

Neuroscience BioPartnering & Investment Forum

CEO Jerry McLaughlin will present at the Neuroscience BioPartnering & Investment Forum on Tuesday, February 23, at 3:35 pm Eastern Time. The BIO CEO & Investor Conference is being held at The New York Academy of Sciences.

February 2, 2016

BIO CEO & Investor Conference

CEO Jerry McLaughlin will present in the CNS/Neurological Track on Monday, February 8, at 10:15 am Eastern Time. The BIO CEO & Investor Conference is being held February 8 and 9 at the Waldorf Astoria New York.

November 7, 2015

Clinical Trials on Alzheimer’s Disease (CTAD)

Clinical Trial in MCI Reducing Hippocampal Overactivity: HOPE4MCI AgeneBio’s Michela Gallagher and Sharon Rosenzweig-Lipson to present in Barcelona on Saturday, November 7, 2015, at 11:45 am